CRISPR-Armed Phages Clear Drug-Resistant E. coli in Kidney Patient
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- SNIPR001, a CRISPR-armed phage cocktail developed by Denmark-based SNIPR, was given intravenously and applied directly to the wounds of a 65-year-old man in California whose antibiotic-resistant E. coli infection had failed conventional treatment after a kidney transplant.
- Within one week of starting phage therapy, the man's open abdominal wounds began healing and a bladder mass shrank from 0.74 litres to 0.37 litres, though he had been switched to stronger antibiotics 11 days earlier, leaving the phages' independent contribution unclear.
- SNIPR co-author Eric van der Helm said the phages may have broken up bacterial biofilms and made the new antibiotics more effective, but the team did not test that mechanism; he called it a potential "synergistic effect."
- SNIPR001 can reportedly kill 90 percent of all E. coli strains and can be delivered orally, intravenously, or topically — more potent than wildtype phages because each virus is equipped with a CRISPR system that chews up specific bacterial DNA sequences.
- A phase II clinical trial is now under way in the US to test whether lowering gut E. coli levels with SNIPR001 reduces bloodstream infections in cancer patients, while SNIPR has already received 12 additional compassionate-use requests since the case.
- The case was reported in Clinical Infectious Diseases (DOI: 10.1093/cid/ciag446), and authors cautioned that no firm conclusions can be drawn from a single patient.
- Phage therapy remains rare because isolating phages matched to a specific infecting bacterium is time-consuming and expensive, which is why companies like SNIPR are engineering broad-spectrum, CRISPR-enhanced cocktails instead of relying on natural isolates.
Why it matters: With 12 additional compassionate-use requests already filed and a US phase II trial underway, SNIPR001 is moving from a one-off rescue case toward a potential new class of CRISPR-enhanced antimicrobials — a pipeline that matters because phage therapy has been stuck for decades on the bottleneck of matching natural viruses to each patient's bug, and engineering away that bottleneck could finally make phage drugs commercially viable.
Ask SkimNews
